Vor Biopharma (VOR) Operating Leases (2020 - 2026)

Vor Biopharma (VOR) has reported Operating Leases for 7 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 90.07% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (down 90.07% YoY), while the FY2025 annual figure was $2.7 million, down 90.15% from the prior year.
• Operating Leases eased to $2.6 million in Q1 2026 per VOR's latest filing, from $2.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $37.4 million in Q2 2022 and bottomed at $2.6 million in Q1 2026.
• Historically, Operating Leases has averaged $26.0 million across 5 years, with a median of $30.2 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases surged 123.41% — and 2025, when it tumbled 90.22%.
• Vor Biopharma's Operating Leases stood at $35.6 million in 2022, then decreased by 10.69% to $31.8 million in 2023, then retreated by 13.24% to $27.6 million in 2024, then sank by 90.15% to $2.7 million in 2025, then fell by 3.24% to $2.6 million in 2026.
• Business Quant data shows VOR's Operating Leases at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.8 million in Q3 2025.